CD24 and cancer: CD24 has been found to be overexpressed in a variety of cancers, including B-cell lymphomas, cholangiocarcinoma, pancreatic adenocarcinoma, urothelial carcinoma, erythroleukemia, gliomas, breast cancer, small cell lung cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, ovarian cancer, primary neuroendocrine carcinomas and prostate carcinomas (8, 148, 215–229).